BOSTON SCIENTIFIC CORP (BSX)

Insider Trading Filed: 2026-05-11

Key Insights

Director Zane Ellen M received an annual equity award of 3,800 restricted shares (valued at $215,000) vesting at the next stockholders' meeting, indicating standard board compensation practices and confidence in future stock performance.
The acquisition was granted at $0.00 transaction price, confirming this is a restricted stock award rather than a market purchase, which is typical for non-officer director compensation.
Post-transaction beneficial ownership stands at 27,934 shares held directly, representing a meaningful personal stake in BSX by a board member and suggesting aligned interests with shareholders.

Insider Trading Filed: 2026-05-11

Key Insights

Director David Wichmann acquired 3,800 shares of BSX common stock on 05/07/2026 at no cost as part of an annual equity award, representing a $215,000 compensation component valued at the grant date closing price.
The restricted stock grant vests in full upon the next annual stockholder meeting, indicating standard director compensation practices rather than market-driven trading activity.
Wichmann's total beneficial ownership increased to 45,382 shares following this transaction, demonstrating ongoing alignment between director interests and shareholder value.

Insider Trading Filed: 2026-05-11

Key Insights

Director Christophe Pierre Weber received a total of 2,907 shares in restricted stock awards (1,767 + 1,140 shares) on 05/07/2026, valued at approximately $315,500, representing standard annual non-employee director compensation rather than discretionary insider buying.
An additional 2,660 deferred stock units were granted, bringing total equity compensation to approximately $466,000, which vests upon the next annual stockholder meeting and will be issued post-separation from the board, indicating routine director compensation practices.
All securities were acquired at $0.0000 transaction price, confirming these are compensation grants rather than open market purchases, with no indication of insider confidence regarding stock valuation through personal buying.
The reporting person holds 3,786 shares of common stock directly and 2,660 deferred stock units following these transactions, representing a modest equity stake typical for non-employee board directors without significant personal investment.

Insider Trading Filed: 2026-05-11

Key Insights

Director Cathy R Smith acquired 6,009 deferred stock units (3,800 + 2,209) on 05/07/2026, representing total equity compensation of approximately $340,000 ($215,000 + $125,000), indicating standard director compensation practices.
The acquisition consists of two components: an annual equity award ($215,000 value) and a cash retainer substitute in DSU form ($125,000 value), both vesting at the next annual stockholder meeting with share issuance deferred until separation from board service.
All acquired securities are held directly (Direct ownership) in deferred form rather than immediate equity, suggesting compliance with standard non-employee director compensation plans rather than insider confidence signals about future stock performance.

Insider Trading Filed: 2026-05-11

Key Insights

Director Pegus Cheryl acquired 5,081 deferred stock units (DSUs) on 05/07/2026, valued at approximately $287,500 total, representing a routine annual equity compensation grant and committee chair retainer.
The DSUs vest upon the next annual stockholder meeting and will be converted to common shares following the director's separation from the board, indicating standard non-employee director compensation practices with no concerning timing.
Total beneficial ownership increased to 10,998 DSUs following these transactions, demonstrating continued alignment between director and shareholder interests through equity-based compensation.
The filing shows no material insider selling pressure, with acquisitions limited to standard annual compensation arrangements rather than discretionary open-market purchases.

Insider Trading Filed: 2026-05-11

Key Insights

Director Susan Morano acquired 5,081 shares total (3,800 restricted shares from annual equity award + 1,281 restricted shares in lieu of cash compensation) on 05/07/2026, bringing her total beneficial ownership to 11,744 shares.
Both equity awards vest upon the next annual stockholder meeting, indicating the company uses performance-aligned compensation structures for board members rather than immediate cash compensation.
The restricted stock grants totaling approximately $287,500 in value ($215,000 annual award + $72,500 cash-in-lieu grant) represent standard director compensation at Boston Scientific, with no indication of insider selling or portfolio liquidation.

Insider Trading Filed: 2026-05-11

Key Insights

Director Jessica L. Mega acquired 3,800 shares of BSX common stock on 05/07/2026 at $0.00 price, representing an annual equity award valued at $215,000 based on the closing price at grant date.
The restricted stock award vests in full at the next annual stockholders meeting, indicating standard director compensation practices rather than open market purchases or discretionary buying activity.
Following this transaction, Mega's total beneficial ownership increased to 12,035 shares held directly, demonstrating continued alignment with company shareholders through equity holdings.

Insider Trading Filed: 2026-05-11

Key Insights

Director Edward Ludwig acquired 3,800 shares of Boston Scientific common stock on 05/07/2026 through an annual equity award in the form of restricted stock, valued at approximately $215,000 based on closing price at grant.
The restricted stock award vests in full upon the next annual stockholder meeting, indicating standard director compensation practices with performance-linked retention incentives.
Post-transaction beneficial ownership stands at 21,779 shares held directly, representing a modest equity stake and demonstrating continued insider alignment with shareholder interests.

Insider Trading Filed: 2026-05-11

Key Insights

Director David C. Habiger acquired 3,800 shares of BSX common stock on 05/07/2026 through an annual equity award valued at $215,000, reflecting ongoing board compensation practices.
The restricted stock grant vests in full at the next annual stockholders meeting, indicating standard director incentive alignment with shareholder interests.
Post-transaction beneficial ownership stands at 9,428 shares held directly, suggesting moderate personal investment by the director in the company.

Current Report Filed: 2026-05-05

Key Insights

Boston Scientific successfully eliminated supermajority voting provisions in its charter, reducing barriers to future takeover attempts and enhancing shareholder voting power with 98.6% approval on the amendment.
The company added officer exculpation provisions under Delaware law, which provides legal protection for officers in certain circumstances but received notably lower shareholder support (87.5% approval) compared to other governance items.
All 10 board directors were re-elected with strong support, though David Habiger and Cathy Smith received lower vote percentages (85.9% and 92.6% respectively) compared to other nominees, potentially signaling selective investor concerns.
Stockholders decisively rejected both proposals regarding special meeting rights (shareholders owning 25% stock), with the stockholder proposal receiving only 42.8% support, indicating investor preference for maintaining existing governance controls.
The company expanded its Employee Stock Purchase Plan with overwhelming approval (99.8%), suggesting management confidence in employee engagement and stock-based compensation strategy.

Quarterly Report Filed: 2026-05-01

Key Insights

Boston Scientific completed multiple strategic acquisitions in Q1 2026, including Penumbra Inc. (January 15), Nalu Medical (January 27), and Scivita Medical, indicating aggressive portfolio expansion and M&A activity to strengthen competitive positioning.
The filing demonstrates active hedging strategies across foreign exchange contracts and net investment hedges, suggesting management is managing currency exposure and international operational risks as the company operates globally.
The company maintains structured debt obligations including Senior Notes due 2027 and December 2027 Notes, requiring careful cash flow management and refinancing planning in the near-term maturity window.
Significant intangible assets related to acquisitions, including technology-based intangibles, patents, and in-process R&D, indicate substantial goodwill and integration risk that could impact future earnings if synergy targets are not achieved.

Current Report Filed: 2026-04-22

Key Insights

Boston Scientific announced Q1 2026 financial results on April 22, 2026, providing investors with the first quarterly performance update of the year through the press release filed as Exhibit 99.1.
The filing confirms the company maintains dual securities listings on NYSE (common stock under ticker BSX and senior notes due 2027 under ticker BSX27), indicating active debt management alongside equity operations.
As a non-emerging growth company, Boston Scientific is subject to full SEC compliance requirements and SOX auditing standards, suggesting it is an established large-cap medical device manufacturer with significant market presence.

Current Report Filed: 2026-03-30

Key Insights

Boston Scientific announced positive results from two key clinical trials, HI-PEITHO and CHAMPION-AF, which could indicate potential product pipeline advancements and growth opportunities.
The company filed this 8-K to disclose the clinical trial results, suggesting these are material events that could impact the stock price.
Investors should monitor the progress of these trials and potential regulatory and commercial milestones that could arise from these developments.

Insider Trading Filed: 2026-03-03

Key Insights

Insider Emily Woodworth, SVP and Global Controller, exercised 838 restricted stock units and sold 372 shares of Boston Scientific common stock on March 1, 2026.
The transaction resulted in Woodworth directly owning 2,859 shares of Boston Scientific, down from 3,231 shares prior to the transaction.
Insiders' transactions can provide signals about a company's future prospects, and should be monitored by investors.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Arthur C. Butcher, who is an EVP & Grp Pres at Boston Scientific Corp, acquired 6,851 shares of common stock through the company's 401(k) Retirement Savings Plan, indicating their confidence in the company's performance.
The reporting person still holds a significant direct ownership of 55,792 shares, suggesting they remain invested in the long-term success of Boston Scientific Corp.
The acquisition of shares through the 401(k) plan indicates the reporting person's commitment to the company and their belief in its growth potential.

Current Report Filed: 2026-02-26

Key Insights

Boston Scientific entered into a $3 billion revolving credit agreement that matures in 2031, providing the company with significant financial flexibility.
The agreement includes an option to extend the maturity by one year, subject to lender approval, indicating the company's ability to negotiate favorable terms.
The agreement allows Boston Scientific to exclude certain cash litigation payments from its financial covenants, potentially mitigating the impact of legal disputes on its leverage ratio.

Current Report Filed: 2026-02-23

Key Insights

Boston Scientific announced the appointment of two new directors, Catherine R. Smith and Christophe P. Weber, to its Board, effective February 18, 2026.
The Board also approved an increase of $4.0 billion to the company's existing stock repurchase program, bringing the total authorization to $5.0 billion.
The new directors will receive standard non-employee director compensation, including a cash retainer and equity award, prorated for the period until the 2026 annual meeting.

Annual Report Filed: 2026-02-17

Key Insights

Boston Scientific reported revenue growth of 7% in 2025, driven by strong performance in its medical device segments.
Gross margins improved by 2 percentage points year-over-year, indicating operational efficiency and cost control.
The company provided positive guidance for 2026, projecting 5-8% revenue growth and margin expansion, which could signal continued momentum.

Current Report Filed: 2026-02-05

Key Insights

Boston Scientific announced that Yoshiaki Fujimori, a member of the Board of Directors since 2016, will not stand for re-election at the 2026 Annual Meeting.
The company stated that Fujimori's decision is not the result of any disagreement with the company, and the Board will evaluate whether to add new directors after his departure.
This change in Board composition could signal a shift in the company's strategic priorities or leadership, which investors should monitor for potential impacts.

Current Report Filed: 2026-02-04

Key Insights

Boston Scientific Corporation reported financial results for the fourth quarter and full year 2025, indicating the company's performance was in line with market expectations.
The company's senior notes due 2027 are publicly traded, providing investors with an additional fixed-income investment option from the medical device manufacturer.
The 8-K filing does not indicate any major leadership changes or material agreements that would significantly impact the company's operations or future outlook.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information